Variability in response to medicines in older people: Phenotypic and genotypic factors

Clinical Pharmacology and Therapeutics

Volumn 85, Issue 4, 2009, Pages 431-433

  McLachlan, A J ^a,b   Hilmer, S N ^a,c   Le Couteur, D G ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Department of Microbiology and Infectious Diseases   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; CYTOCHROME P450; DIAZEPAM; DRUG METABOLITE; GLYCOPROTEIN P; PARACETAMOL; VERAPAMIL; VITAMIN D; WARFARIN;

ADIPOSE TISSUE; AGED; AGING; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; DIET SUPPLEMENTATION; DOSE CALCULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; ENZYME ACTIVITY; FRAIL ELDERLY; GENOTYPE; GERIATRIC PATIENT; HEART ATRIUM FIBRILLATION; HUMAN; LEAN BODY WEIGHT; MALNUTRITION; OPTIMAL DRUG DOSE; PHARMACODYNAMICS; PHARMACOGENOMICS; PHENOTYPE; POLYPHARMACY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THROMBOEMBOLISM; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; AGING; GENETIC VARIATION; GENOTYPE; HUMANS; PHARMACEUTICAL PREPARATIONS; PHENOTYPE;

EID: 62649085032     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.1     Document Type: Article

References (30)

1. Evans, W.E. & McLeod, H.L. Pharmacogenomics - drug disposition, drug targets, and side effects. N. Engl. J. Med. 348, 538-549 (2003).
2. Hilmer, S.N., McLachlan, A.J. & Le Couteur, D.G. Clinical pharmacology in geriatric patients. Fundam. Clin. Pharmacol. 21, 217-230 (2007).
3. McLean, A.J. & Le Couteur, D.G. Aging biology and geriatric clinical pharmacology. Pharmacol. Rev. 56, 163-184 (2004).
4. Wilkinson, G.R. Drug metabolism and variability among patients in drug response. N. Engl. J. Med. 352, 2211-2221 (2005).
5. Tulner, L.R., Frankfort, S.V., Gijsen, G.J., van Campen, J.P., Koks, C.H. & Beijnen, J.H. Drug-drug interactions in a geriatric outpatient cohort: prevalence and relevance. Drugs Aging 25, 343-355 (2008).
6. Finch, C.E. & Tanzi, R.E. Genetics of aging. Science 278, 407-411 (1997).
7. Zahn, J.M. et al. AGEMAP: a gene expression database for aging in mice. PLoS Genet. 3, e201 (2007).
8. Bathum, L., Andersen-Ranberg, K., Boldsen, J., Brøsen, K. & Jeune, B. Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevity. Role of CYP2D6 and CYP2C19 in longevity. Eur. J. Clin. Pharmacol. 54, 427-430 (1998).
9. Wynne, H. Drug metabolism and ageing. J. Br. Menopause Soc. 11, 51-56 (2005).
10. Butler, J.M. & Begg, E.J. Free drug metabolic clearance in elderly people. Clin. Pharmacokinet. 47, 297-321 (2008).
11. Schwartz, J.B. The current state of knowledge on age, sex and their interactions on clinical pharmacology. Clin. Pharmacol. Ther. 82, 87-96 (2007).
12. Vestal, R.E., Cusack, B.J., Crowley, J.J. & Loi, C.M. Aging and the response to inhibition and induction of theophylline metabolism. Exp. Gerontol. 28, 421-433 (1993).
13. Gorski, J.C. et al. The effect of age, sex and rifampicin administration on intestinal and hepatic cytochrome P4503A activity. Clin. Pharmacol. Ther. 74, 275-287 (2003).
14. Mallet, L., Spinewine, A. & Huang, A. The challenge of managing drug interactions in elderly people. Lancet 370, 185-191 (2007).
15. Punyawudho, B. et al. Population pharmacokinetics of lamotrigine in elderly patients. J. Clin. Pharmacol. 48, 455-463 (2008).
16. Vestal, R.E., McGuire, E.A., Tobin, J.D., Andres, R., Norris, A.H. & Mezey, E. Aging and ethanol metabolism. Clin. Pharmacol. Ther. 21, 343-354 (1977).
17. Klotz, U., Avant, G.R., Hoyumpa, A., Schenker, S. & Wilkinson, G.R. The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J. Clin. Invest. 55, 347-359 (1975).
18. Brenner, S.S. & Klotz, U. P-glycoprotein function in the elderly. Eur. J. Clin. Pharmacol. 60, 97-102 (2004).
19. Toornvliet, R. et al. Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clin. Pharmacol. Ther. 79, 540-548 (2006).
20. Fried, L.P. et al. Frailty in older adults: evidence for a phenotype. J. Gerontol. A Biol. Sci. Med. Sci. 56, M146-M156 (2001).
21. Wynne, H.A., Yelland, C., Cope, L.H., Boddy, A., Woodhouse, K.W. & Bateman, D.N. The association of age and frailty with the pharmacokinetics and pharmacodynamics of metoclopramide. Age Ageing 22, 354-359 (1993).
22. Schwartz, J.B. Erythromycin breath test results in elderly, very elderly, and frail elderly persons. Clin. Pharmacol. Ther. 79, 440-448 (2006).
23. Hubbard, R.E., O'Mahony, M.S., Calver, B.L. & Woodhouse, K.W. Plasma esterases and inflammation in ageing and frailty. Eur. J. Clin. Pharmacol. 64, 895-900 (2008).
24. Morgan, E.T. et al. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab. Dispos. 36, 205-216 (2008).
25. Vesell, E.S. Genetic and environmental factors affecting drug disposition in man. Clin. Pharmacol. Ther. 22, 659-679 (1977).
26. Perera, V., Bajorek, B.V., Matthews, S. & Hilmer, S.N. The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation. Age Ageing (2009); e-pub ahead of print 16 January 2009.
27. Miao, L., Yang, J., Huang, C. & Shen, Z. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur. J. Clin. Pharmacol. 63, 1135-1141 (2007).
28. Gage, B.F. et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84, 326-331 (2008).
29. Sjöqvist, F. & Eliasson, E. The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants. Clin. Pharmacol. Ther. 81, 899-902 (2007).
30. Le Couteur, D.G. & Kendig, H. Pharmaco-epistemology for the prescribing geriatrician. Australas. J. Ageing 27, 3-7 (2008).